Dalton is a technology company.
Dalton has raised $1.0M across 1 funding round.
Dalton has raised $1.0M in total across 1 funding round.
Dalton has raised $1.0M in total across 1 funding round.
Dalton's investors include Adjacent, Pitchdrive, Pieterjan Bouten.
DaltonTx is an AI-powered platform revolutionizing drug discovery by providing adaptive intelligence for pharma, biotech, and CROs, covering the full lifecycle from data ingestion to experiment prioritization for small molecules and biologics.[1] It serves scientists and R&D teams, solving inefficiencies in discovery timelines, economics, and outcomes through technology that learns from experiments, models, and users—offering seamless workflow integration without relying solely on predictive models.[1] Backed by investors like redalpine, IQ Capital, and Seedcamp, it demonstrates strong early momentum in a high-stakes biotech AI sector.[1]
(Note: Multiple entities match "Dalton" in tech, including a website optimization tool at getdalton.com for e-commerce conversion testing[2] and DALTON TECHNOLOGY LTD, a UK firm in technical textiles and wholesale since 2022[3]. This overview focuses on DaltonTx as the most prominent AI-driven technology company aligning with modern innovation trends.[1])
DaltonTx was founded by a team blending software engineering, machine learning, and deep drug discovery expertise, with roots in academic excellence from the University of Oxford and decades of industry experience.[1] Built explicitly by scientists for scientists, it emerged to tackle complex R&D challenges in biologics and small molecules, where traditional methods fall short—gaining traction through proven performance on breakthrough discovery problems.[1] Early validation came via investments from redalpine, IQ Capital, and Seedcamp, signaling confidence in its adaptive AI approach amid rising AI-biotech convergence.[1]
DaltonTx rides the explosive trend of AI transforming drug discovery, where machine learning accelerates R&D amid surging demand for faster, cheaper therapies in biologics and small molecules.[1] Timing is ideal post-2020s AI boom, with market forces like ballooning drug development costs (often $2B+ per asset) and talent shortages favoring platforms that democratize advanced tools for non-experts.[1] It influences the ecosystem by empowering CROs and biotechs to compete with big pharma, fostering innovation cycles that could shorten discovery from years to months—amplifying AI's role in precision medicine.[1]
DaltonTx is poised to scale as AI-drug discovery matures, potentially capturing share in a market projected to hit tens of billions by integrating deeper with lab automation and multi-omics data.[1] Trends like generative AI for molecules and regulatory nods for AI-derived candidates will propel it, evolving its influence from enabler to standard infrastructure—much like cloud did for software. Watch for partnerships with major pharma and expansion into predictive toxicology, solidifying its backbone role in tomorrow's medicines.[1] This positions DaltonTx as a high-conviction play in biotech's AI renaissance, directly addressing the query's tech innovator lens.
Dalton has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $1.0M Seed | Adjacent, Pitchdrive, Pieterjan Bouten |